Show simple item record

dc.contributor.authorWilding, CPen_US
dc.contributor.authorElms, MLen_US
dc.contributor.authorJudson, Ien_US
dc.contributor.authorTan, A-Cen_US
dc.contributor.authorJones, RLen_US
dc.contributor.authorHuang, PHen_US
dc.date.accessioned2019-11-06T10:11:08Z
dc.date.issued2019-11-13en_US
dc.identifier.citationExpert review of anticancer therapy, 2019, 19 (11), pp. 971 - 991en_US
dc.identifier.issn1473-7140en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3402
dc.identifier.eissn1744-8328en_US
dc.identifier.doi10.1080/14737140.2019.1686979en_US
dc.description.abstractIntroduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes including proliferation, migration, and apoptosis. As such, targeting these proteins with small molecule tyrosine kinase inhibitors (TKI) has led to significant advances in the treatment of a number of cancer types.Areas covered: Soft tissue sarcomas (STS) are a heterogeneous and challenging group of rare cancers to treat, but the approval of the TKI pazopanib for the treatment of advanced STS demonstrates that this class of drugs may have broad utility against a range of different sarcoma histological subtypes. Since the approval of pazopanib, a number of other TKIs have entered clinical trials to evaluate whether their activity in STS matches the promising results seen in other solid tumors. In this article, we review the emerging role of TKIs in the evolving landscape of sarcoma treatment.Expert opinion: As our biological understanding of response and resistance of STS to TKIs advances, we anticipate that patient management will move away from a 'one size fits all' paradigm toward personalized, multi-line, and patient-specific treatment regimens where patients are treated according to the underlying biology and genetics of their specific disease.en_US
dc.formatPrint-Electronicen_US
dc.format.extent971 - 991en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectSarcomaen_US
dc.subjectSulfonamidesen_US
dc.subjectPyrimidinesen_US
dc.subjectProtein Kinase Inhibitorsen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectProtein-Tyrosine Kinasesen_US
dc.subjectPrecision Medicineen_US
dc.titleThe landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737140.2019.1686979en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2019-11-13en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert review of anticancer therapyen_US
pubs.issue11en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublisheden_US
pubs.volume19en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSarcoma Clinical Trialsen_US
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorHuang, Paulen_US
dc.contributor.icrauthorJudson, Ianen_US
dc.contributor.icrauthorWilding, Christopheren_US
dc.contributor.icrauthorElms, Marken_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/